Cargando…

Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity

PURPOSE: It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodia, R., Meloni, P. E., Mascia, C., Balestrieri, C., Ruggiero, V., Serra, G., Conti, M., Loi, M., Pes, F., Onali, S., Perra, A., Littera, R., Velluzzi, F., Mariotti, S., Chessa, L., Boi, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859881/
https://www.ncbi.nlm.nih.gov/pubmed/36048357
http://dx.doi.org/10.1007/s40618-022-01909-0
_version_ 1784874458157154304
author Rodia, R.
Meloni, P. E.
Mascia, C.
Balestrieri, C.
Ruggiero, V.
Serra, G.
Conti, M.
Loi, M.
Pes, F.
Onali, S.
Perra, A.
Littera, R.
Velluzzi, F.
Mariotti, S.
Chessa, L.
Boi, F.
author_facet Rodia, R.
Meloni, P. E.
Mascia, C.
Balestrieri, C.
Ruggiero, V.
Serra, G.
Conti, M.
Loi, M.
Pes, F.
Onali, S.
Perra, A.
Littera, R.
Velluzzi, F.
Mariotti, S.
Chessa, L.
Boi, F.
author_sort Rodia, R.
collection PubMed
description PURPOSE: It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may induce thyroid alterations. METHODS: A total of 113 HCV patients, subdivided at the time of the enrollment in naïve group (n = 64) and in IFN-α group (n = 49) previously treated with pegylated interferon-α and ribavirin, were evaluated for thyroid function and autoimmunity before and after 20–32 weeks of DAAs. RESULTS: Before starting DAAs, a total of 8/113 (7.1%) patients showed Hashimoto's thyroiditis (HT) all belonging to IFN-α group (8/49, 16.3%), while no HT cases were found in the naïve group. Overall, 7/113 (6.2%) patients were hypothyroid: 3/64 (4.7%) belonging to naïve group and 4/49 (8.2%) to IFN-α group. Furthermore, a total of 8/113 patients (7.1%) showed subclinical hyperthyroidism: 2/64 (3.1%) were from naïve group and 6/49 (12.2%) from IFN-α group. Interestingly, after DAAs therapy, no new cases of HT, hypothyroidism and hyperthyroidism was found in all series, while 6/11 (54.5%) patients with non-autoimmune subclinical thyroid dysfunction became euthyroid. Finally, the only association between viral genotypes and thyroid alterations was genotype 1 and hypothyroidism. CONCLUSIONS: This study supports evidence that DAAs have a limited or missing influence on thyroid in patients with HCV-related diseases. Moreover, it provides preliminary evidence that subclinical non-autoimmune thyroid dysfunction may improve after HCV infection resolution obtained by DAAs.
format Online
Article
Text
id pubmed-9859881
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98598812023-01-22 Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity Rodia, R. Meloni, P. E. Mascia, C. Balestrieri, C. Ruggiero, V. Serra, G. Conti, M. Loi, M. Pes, F. Onali, S. Perra, A. Littera, R. Velluzzi, F. Mariotti, S. Chessa, L. Boi, F. J Endocrinol Invest Original Article PURPOSE: It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this prospective study was to evaluate if DAAs therapy may induce thyroid alterations. METHODS: A total of 113 HCV patients, subdivided at the time of the enrollment in naïve group (n = 64) and in IFN-α group (n = 49) previously treated with pegylated interferon-α and ribavirin, were evaluated for thyroid function and autoimmunity before and after 20–32 weeks of DAAs. RESULTS: Before starting DAAs, a total of 8/113 (7.1%) patients showed Hashimoto's thyroiditis (HT) all belonging to IFN-α group (8/49, 16.3%), while no HT cases were found in the naïve group. Overall, 7/113 (6.2%) patients were hypothyroid: 3/64 (4.7%) belonging to naïve group and 4/49 (8.2%) to IFN-α group. Furthermore, a total of 8/113 patients (7.1%) showed subclinical hyperthyroidism: 2/64 (3.1%) were from naïve group and 6/49 (12.2%) from IFN-α group. Interestingly, after DAAs therapy, no new cases of HT, hypothyroidism and hyperthyroidism was found in all series, while 6/11 (54.5%) patients with non-autoimmune subclinical thyroid dysfunction became euthyroid. Finally, the only association between viral genotypes and thyroid alterations was genotype 1 and hypothyroidism. CONCLUSIONS: This study supports evidence that DAAs have a limited or missing influence on thyroid in patients with HCV-related diseases. Moreover, it provides preliminary evidence that subclinical non-autoimmune thyroid dysfunction may improve after HCV infection resolution obtained by DAAs. Springer International Publishing 2022-09-01 2023 /pmc/articles/PMC9859881/ /pubmed/36048357 http://dx.doi.org/10.1007/s40618-022-01909-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Rodia, R.
Meloni, P. E.
Mascia, C.
Balestrieri, C.
Ruggiero, V.
Serra, G.
Conti, M.
Loi, M.
Pes, F.
Onali, S.
Perra, A.
Littera, R.
Velluzzi, F.
Mariotti, S.
Chessa, L.
Boi, F.
Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
title Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
title_full Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
title_fullStr Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
title_full_unstemmed Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
title_short Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
title_sort direct-acting antivirals used in hcv-related liver disease do not affect thyroid function and autoimmunity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859881/
https://www.ncbi.nlm.nih.gov/pubmed/36048357
http://dx.doi.org/10.1007/s40618-022-01909-0
work_keys_str_mv AT rodiar directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT melonipe directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT masciac directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT balestrieric directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT ruggierov directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT serrag directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT contim directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT loim directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT pesf directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT onalis directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT perraa directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT litterar directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT velluzzif directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT mariottis directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT chessal directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity
AT boif directactingantiviralsusedinhcvrelatedliverdiseasedonotaffectthyroidfunctionandautoimmunity